No Known Mutations

**IRB#9902**  
Nivolumab or Nivolumab + Ipilimumab in Advanced or Metastatic Solid Tumors

**IRB# 17521**  
SNDX-6352 with or without Durvalumab in Patients with Unresectable, Recurrent, Locally Advanced, or Metastatic Solid Tumors

**IRB# 18303**  
Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors

**IRB# 18498**  
Study of BA3021 in patients with locally advanced solid tumors

**IRB# 19388**  
A Phase 1b Dose Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors

**IRB# 21194**  
A Phase 1 study of SGN-CD228A in select advanced solid tumors

**IRB# 21508**  
Study of ORIC-101 in Combination With Anticancer Therapy

**IRB# 21464**  
A Study of mRNA-2752 for Intratumoral Injection Alone and in Combination with Immune Checkpoint Blockade

No Known Mutations

**IRB# 21766**  
A Phase I/Ib study of GEN-001 in Combination with Avelumab in Patients with Advanced Solid Tumors Who Have Progressed during or after Treatment with Anti-PD-(L)1 therapy

**IRB# 22797**  
A Phase 1b Dose Escalation Study to evaluate GS-3583, a FLT3 agonist Fc fusion protein, in Subjects with Advanced Solid Tumors

**IRB# 22082**  
A Phase 1b, Open-label, Dose-escalation and Dose-expansion Study to Evaluate Camidanlumab Tesirine (ADCT-301) as Monotherapy or in Combination in Patients With Selected Advanced Solid Tumors

**IRB# 22760**  
Study of Magrolimab in Participants With Solid Tumors

**IRB# 23157**  
Study of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies

**IRB# 23236**  
Study of SGN-STNV in Advanced Solid Tumors

**IRB# 24483**  
Phase 1 study of BAL0891 as monotherapy and in combination with chemotherapy in patients with advanced solid tumors

**IRB# 24406**  
A Phase 1 study of KSO-4279 alone and in combination in patients with advanced solid tumors

---

**Key**:  
- Open for Enrollment  
- In Development  
- Enrollment on Hold

http://www.ohsu.edu/research/rda/so/knight.php
Phase I Program

Note: Other Phase 1 Studies may be open at the Knight, please click here to view

- **Fusion-NTRK (previously treated)**
  - IRB 17674: Loxo-195 in fusion-NTRK (previously treated) solid tumors
  - IRB 21819: A Phase 1-2 Study of ASTX029 in Subjects With Advanced Solid Tumors

- **RET Mutations**
  - IRB# 16676: BLU-667 in thyroid cancer, non-small cell lung cancer and advanced solid tumors
  - IRB 18164: A Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors with Increased RET Activity

- **Solid tumors with gene aberrations in the mitogen-activated protein kinase (MAPK) pathway**
  - IRB 21548: A Phase 1 Study of AMG 650 in Subjects With Advanced Solid Tumors

- **TNBC, HGSOC, Endometrial, and advanced solid tumor with Tp53 mutation**
  - IRB 21548: A Phase 1 Study of AMG 650 in Subjects With Advanced Solid Tumors

6/10/2022

http://www.ohsu.edu/research/rda/so/knight.php
IRB 22580
CRESTONE:
A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors

IRB 2223
A Phase 1b Open-Label Study to Evaluate PY159 as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

IRB 2580 CRESTONE:
A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors

IRB 22902
A PHASE 2, SUBPROTOCOL OF DAY101 MONOTHERAPY FOR PATIENTS WITH RECURRENT, PROGRESSIVE, OR REFRACTORY SOLID TUMORS WITH ACTIVATING BRAF GENE FUSION

IRB 22223
A Phase 1a/1b Open-Label Study to Evaluate PC14586 in Patients with Advanced Solid Tumors Harboring a p53 Y220C Mutation

IRB 22966
A Phase 1 Study of 23ME-00610 in Patients With Advanced Solid Malignancies

IRB 21998
A Phase 1/2 Open-label study to evaluate PC14586 in Patients with Advanced Solid Tumors Harboring a p53 Y220C Mutation

IRB 22925
A Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors

IRB 22986
An open-label study to evaluate VIP152 (BAY 1251152) alone or in combination with pembrolizumab in subjects with advanced cancer

6/10/2022
http://www.ohsu.edu/research/rda/so/knight.php